

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.

**IN THE MATTER OF:** Australian Patent  
Application 696764 (73941/94). In the name of:  
Human Genome Sciences Inc.

-and-

**IN THE MATTER OF:** Opposition thereto by  
Ludwig Institute for Cancer Research, under  
Section 59 of the Patents Act.

### STATUTORY DECLARATION

I, Susan Power of Cell & Molecular Technologies, Inc., Phillipsburg, New Jersey, United


States of America, declare as follows:

1. I am currently a Senior Molecular Biologist for Cell & Molecular Technologies, Phillipsburg, New Jersey. I have held this position since July, 1999. Prior to that appointment I was a post-doctorate research scientist, studying the molecular biology of retinoids and their role in limb bud development, at the University of Wisconsin, Madison, Wisconsin for two years. Prior to that appointment, I was a post-doctorate research scientist, studying the molecular biology of the transcription factor vHNF1 at the Pasteur Institute in Paris, France for four years. I received my Ph.D. in 1991 in Microbiology, from the National University of Ireland, Galway, Ireland.
2. The Patent Attorneys for Human Genome Sciences (HGS) requested that I perform the following experiments in order to determine whether the 350 amino acid form of VEGF-2 (corresponding to residues 70 to 419 of the 419 amino acid form of VEGF-2) fused in frame with a heterologous signal sequence would result in the expression and secretion of the protein from eukaryotic cells. They have also requested that all experiments that I conducted employ techniques routinely available by March, 1994. I have done this and the experiments I have conducted are described herein. Unless I state otherwise, all methods used herein were available prior to March, 1994.


3. To determine whether the 350 amino acid form of VEGF-2 could be secreted from cells when attached to a heterologous signal sequence, I transfected eukaryotic cells with expression vectors encoding the 419 amino acid form of VEGF-2, or the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence. I grew the transfected cells under conditions to allow the cells to express the gene products encoded by the vectors. At various time points, I collected both cell lysates and culture medium and assayed for the presence of VEGF-2, in order to determine if the cells were secreting VEGF-2. The presence of VEGF-2 in either the cell lysates or culture medium was determined by Western Blot analysis of the samples using a polyclonal antibody to VEGF-2, which recognizes both the precursor form and the processed form of VEGF-2

4. The design of the expression vectors used in the study is as follows:

419 amino acid form of VEGF-2 (followed by a STOP codon at position 420):



350amino acid form of VEGF-2 linked to a heterologous signal sequence (followed by a STOP codon at position 420):



5. The nucleotide sequences encoding the 419 and the 350 amino acid forms of VEGF-2 were obtained directly from the American Type Culture Collection (ATCC). ATCC Deposit No. 97149 contains the nucleotide sequence encoding the 419 amino acid form of VEGF-2. ATCC Deposit No. 75698 contains the nucleotide sequence encoding the 350 amino acid form of VEGF-2. The nucleotide sequence encoding the 419 amino acid form of VEGF-2

was engineered to be flanked by an Eco RI site at the 5' end and a Not I site at its 3' end. The second construct contained the nucleotide sequence encoding the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence, Ig k-chain leader signal sequence, a recognized signal sequence which was available as of March, 1994, and was engineered to contain a Bam HI site at its 5' end and a Not I site at its 3' end. The sequence of each of these constructs was confirmed to be correct and is detailed in Appendix I, attached hereto.

6. Each VEGF-2 construct was subcloned into the expression vector pCMV-I (see attached plasmid map, attached hereto as Appendix II), so that the VEGF-2 sequences were under the control of a CMV-I promoter, a promoter routinely used as of March, 1994. The 419 amino acid form of VEGF-2 was subcloned into the Eco RI/Not I sites of pCMV-I, while the 350 amino acid form of VEGF-2 fused in frame with a heterologous signal sequence, was subcloned into the Bam HI/Not I sites of pCMV-I (see plasmid map, Appendix II).
7. The two VEGF-2 constructs were transiently transfected in duplicate, using the lipofectin method, comparable methods were routinely used as of March, 1994, into the Human Embryonic Kidney cell line, HEK-293 tsA-0, a cell line which was also routinely used as of March, 1994. As a control for transfection efficiency, each construct was co-transfected with the vector pCMV- $\beta$ -gal. The efficiency of transfection was determined by  $\beta$ -gal staining 48 hours after transfection. As a negative control the vector pCMV-I without an insert was transfected in parallel.
8. The transfection design is as follows:
  - 10 dishes transfected with: pCMV-I-VEGF-419;
  - 10 dishes transfected with: pCMV-I-signal sequence-VEGF-350;
  - 10 dishes transfected: pCMV-I;
  - 2 dishes transfected with: pCMV-I-VEGF-419 + pCMV- $\beta$ -gal; and
  - 2 dishes transfected with: pCMV-I-signal sequence-VEGF-350 + pCMV- $\beta$ -gal.

9. After transfection, DMEM medium containing 3% serum was added to the cells. Aliquots of cell extracts and conditioned medium were prepared from each transfection at: T<sub>0</sub> hours, T<sub>16</sub> hours, T<sub>24</sub> hours, T<sub>48</sub> hours and T<sub>72</sub> hours, in duplicate.
  
10. At the time of harvesting the cells and medium were treated as follows:  
Medium: Harvested medium was concentrated 3 fold using Centricon 10 concentrator devices. One volume of 2 x PAGE loading dye was added to each sample.  
Cell Extracts: The cells were harvested by trypsinization and collected by centrifugation. The cell pellet was resuspended and lysed in 250µl of 1x PAGE loading buffer.
  
11. To determine the transfection efficiency, dishes transfected with the pCMV-β-gal construct were fixed and stained for β-gal activity 48 hours after transfection. All dishes were found to have the same percentage of transfected cells (70%).
  
12. Each protein sample was subjected to Western analysis as outlined below. Prior to loading on to a 12% (w/v) Tris-Glycine SDS-Polyacrylamide gel, the samples were boiled for 5 minutes and cooled on ice. The two end lanes of each gel contained the appropriately sized molecular weight markers to estimate the migration rate of proteins predicted to run in the 16 to 85 kDa size range. The samples were electrophoresed according to standard conditions.
  
13. Following electrophoresis, the samples were transferred to a PVDF membrane. Each membrane was blocked by a one hour incubation in phosphate buffered saline (PBS) containing 3% Bovine Serum Albumin (BSA). The blot was then incubated at 4°C in PBS containing 0.1% BSA and 500ng/ul of purified rabbit anti-VEGF-2 antibody, a polyclonal antibody which recognizes the precursor form and the processed form of VEGF-2. After three 5 minute washes in PBS containing 0.1% Tween, the blot was incubated for 1 hour in PBS containing 0.1% BSA and a 1:3000 dilution of Goat Anti-Rabbit IgG

Horse Radish Peroxidase (HRP) conjugated antibody. The blot was washed three times for 5 minutes in PBS containing 0.1% BSA. The blot was developed with 2ml/blot of ECL detection reagent (obtained from Amersham) for one minute and then exposed directly to Polaroid films for approximately 5 seconds.

14. The result of the experiment is shown in Figure 1, attached hereto. The samples included in the figure are as follows:

**Immunoblot analysis of VEGF derivatives transiently expressed in HEK293T cells**

| Lane  | Pellet/Supernatant | 350aa -signal / 419aa | T (h) post-transfection |
|-------|--------------------|-----------------------|-------------------------|
| Gel 1 |                    |                       |                         |
| 1     | P                  | 419                   | 24                      |
| 2     | S                  | 419                   | 24                      |
| 3     | P                  | 350-signal            | 24                      |
| 4     | S                  | 350-signal            | 24                      |
| 5     | P                  | 350-signal            | 24                      |
| 6     | S                  | 350-signal            | 24                      |
| 7     | P                  | negative control      | 24                      |
| 8     | S                  | positive control      | 48                      |
| Gel 2 |                    |                       |                         |
| 9     | P                  | 419                   | 48                      |
| 10    | S                  | 419                   | 48                      |
| 11    | P                  | 419                   | 48                      |
| 12    | S                  | 419                   | 48                      |
| 13    | P                  | 350-signal            | 48                      |
| 14    | S                  | 350-signal            | 48                      |

|          |   |                  |    |
|----------|---|------------------|----|
| 15       | P | 350-signal       | 48 |
| 16       | S | 350-signal       | 48 |
| 17       | P | negative control |    |
| 18       | S | negative control |    |
| Gel<br>3 |   |                  |    |
| 19       | P | 419              | 72 |
| 20       | S | 419              | 72 |
| 21       | P | 419              | 72 |
| 22       | S | 419              | 72 |
| 23       | P | 350-signal       | 72 |
| 24       | S | 350-signal       | 72 |
| 25       | S | 350-signal       | 72 |
| 26       | P | 350-signal       | 72 |

15. The Western Blot analysis indicates that a doublet of approximately 30kDa was present in the medium collected from the transfection of both the 419 amino acid form of VEGF-2 and the 350 amino acid-VEGF-2 signal sequence constructs (see Figure 1). The secreted protein was visible beginning at 16 hours after transfection. The secreted product from cells containing the 419 amino acid construct and the 350 amino acid-VEGF2 signal sequence construct are approximately the same size.

AND I declare that all the statements made in this Declaration are of my own are true in every particular, and that all statements made on information and belief are believed to be true.

Sworn by the said Susan Power, Susan Power at  
Phillipsburg, New Jersey, on this 3<sup>rd</sup> day of December 2000;  
before me Maryann White  
Notary Public

MARYANN WHITE  
NOTARY PUBLIC, State of New York  
No. 4883761  
Qualified in Nassau County  
Certification Filed in New York County  
Commission Expires January 26, 2001

\*\* TOTAL PAGE.07 \*\*

# VEGF-2 350aa +Signal Sequence:

DpnI  
 BamHI  
 +1 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu  
 1 GGATCCGCCA CCATGGAGAC AGACACACTC CTGCTATGGG TACTGCTGCT  
 CCTAGGCGGT GGTACCTCTG TCTGTGTGAG GACGATACCC ATGACGACGA  
 SspI  
 +1 Leu Trp Val Pro Gly Ser Thr Gly Asp Met Thr Val Leu Tyr Pro Glu Tyr Trp  
 51 CTGGGTTCCA GGTTCCTACTG GTGACATGAC TGTACTCTAC CCAGAATATT  
 GACCCAAGGT CCAAGGTGAC CACTGTACTG ACATGAGATG GGTCTTATAA  
 DdeI  
 +1 Trp Lys Met Tyr Lys Cys Gln Leu Arg Lys Gly Gly Trp Gln His Asn Arg  
 101 GGAATATGTA CAAGTGTGAG CTAAGGAAAG GAGGCTGGCA ACATAACAGA  
 CCTTTTACAT GTTCACAGTC GATTCCTTTC CTCCGACCGT TGTATTGTCT  
 PstI  
 +1 Glu Gln Ala Asn Leu Asn Ser Arg Thr Glu Glu Thr Ile Lys Phe Ala Ala  
 151 GAACAGGCCA ACCTCAACTC AAGGACAGAA GAGACTATAA AATTGCTGTC  
 CTGTCCGCT TGGAGTTGAG TTCCTGTCTT CTCTGATATT TTAAACGACG  
 DpnI  
 PstI BglII  
 +1 Ala Ala His Tyr Asn Thr Glu Ile Leu Lys Ser Ile Asp Asn Glu Trp Arg Lys  
 201 AGCACATTAT AATACAGAGA TCTTGAAAAG TATTGATAAT GAGTGGAGAA  
 TCGTGTAATA TTATGTCTCT AGAAGCTTTC ATAAGTATTA CTCACCTCTT  
 SphI  
 +1 Ly: Thr Gln Cys Met Pro Arg Glu Val Cys Ile Asp Val Gly Lys Glu Phe  
 251 AGACTCAATG CATGCCACGG GAGGTGTGTA TAGATGTGGG GAAGGAGTTT  
 TCTGAGTTAC GTACGGTGCC CTCCACACAT ATCTACACCC CTTCTCTCAA  
 NruI  
 +1 Gly Val Ala Thr Asn Thr Phe Phe Lys Pro Pro Cys Val Ser Val Tyr Arg  
 301 GGAGTCGCGA CAAACACCTT CTTTAAACCT CCATGTGTGT CCGTCTACAG  
 CCTCAGCGCT GTTTGTGGAA GAAATTTGGA GTTACACACA GGCAGATGTC  
 PstI  
 +1 Arg Cys Gly Gly Cys Cys Asn Ser Glu Gly Leu Gln Cys Met Asn Thr Ser Thr  
 351 ATGTGGGGGT TGCTGCAATA GTGAGGGGCT GCAGTGCATG AACACCAGCA  
 TACACCCCCA ACGACGTTAT CACTCCCCGA CGTCACGTAC TTGTGGTCTG  
 DdeI  
 +1 Th Ser Tyr Leu Ser Lys Thr Leu Phe Glu Ile Thr Val Pro Leu Ser Gln  
 401 CGAGCTACCT CAGCAAGACG TTATTTGAAA TTACAGTGCC TCTCTCTCAA  
 GCTCGATGGA GTCGTTCTGC AATAAACTTT AATGTCACGG AGAGAGAGTT  
 +1 Gly Pro Lys Pro Val Thr Ile Ser Phe Ala Asn His Thr Ser Cys Arg Cys  
 451 GGCCCCAAAC CAGTAACAAT CAGTTTTGCC AATCACACTT CCTGCCGATG  
 CCGGGGTTTG GTCATTGTTA GTCAAACGG TTAGTGTGAA GGACGGCTAC  
 +1 Cys Met Ser Lys Leu Asp Val Tyr Arg Gln Val His Ser Ile Ile Arg Arg Ser  
 501 CATGTCTAAA CTGGATGTTT ACAGACAAGT TCATTCCATT ATTAGACGTT  
 GTACAGATTT GACCTACAAA TGTCTGTTCA AGTAAGGTAA TAATCTGCAA  
 +1 Ser Leu Pro Ala Thr Leu Pro Gln Cys Gln Ala Ala Asn Lys Thr Cys Pro  
 551 CCCTGCCAGC AACACTACCA CAGTGTGAGG CAGCGAACA GACCTGCCCC  
 GGGACGGTCG TTGTGATGGT GTCACAGTCC GTCGCTTGTT CTGGACGGGG



Friday, November 03, 2000 07:08:31 PM Page 2

# VEGF-2 419aa Sequence:

```

EcoRI
+1  Met His Leu Leu Gly Phe Phe Ser Val Ala
1  GAATTCGTGG GTCCTTCCAC CATGCACTTG CTGGGCTTCT TCTCTGTGGC
   CTTAAGCACC CAGGAAGGTG GTACGTGAAC GACCCGAAGA AGAGACACCG

SmaI
XmaI
AvaI
NruI
+1  Ala Cys Ser Leu Leu Ala Ala Ala Leu Leu Pro Gly Pro Arg Glu Ala Pro Ala
51  GTGTTCTCTG CTCGCCGCTG CGCTGCTCCC GGGTCCTCGC GAGGCGCCCCG
   CACAAGAGAC GAGCGGCGAC GCGACGAGGG CCCAGGAGCG CTCCGCGGGC

+1  Ala Ala Ala Ala Ala Phe Glu Ser Gly Leu Asp Leu Ser Asp Ala Glu Pro
101 CCGCCGCCGC CGCCTTCGAG TCCGGACTCG ACCTCTCGGA CGCGGAGCCC
   GGCGGCGGCG GCGGAAGCTC AGGCCTGAGC TGGAGAGCCT GCGCCTCGGG

DpnI
BglII
+1  Asp Ala Gly Glu Ala Thr Ala Tyr Ala Ser Lys Asp Leu Glu Glu Gln Leu
151 GACGCGGGCG AGGCCACGGC TTATGCAAGC AAAGATCTGG AGGAGCAGTT
   CTGCGCCCCG TCCGGTGCCG AATACGTTCC TTTCTAGACC TCCTCGTCAA

SspI
+1  Leu Arg Ser Val Ser Ser Val Asp Glu Leu Met Thr Val Leu Tyr Pro Glu Tyr
201 ACGGTCTGTG TCCAGTGTAG ATGAATCAT GACTGTACTC TACCCAGAAT
   TGCCAGACAC AGGTCACATC TACTTGAGTA CTGACATGAG ATGGGTCTTA

SspI
DdeI
+1  Tyr Trp Lys Met Tyr Lys Cys Gln Leu Arg Lys Gly Gly Trp Gln His Asn
251 ATTGGAAAAT GTACAAGTGT CAGCTAAGGA AAGGAGGCTG GCAACATAAC
   TAACCTTTTA CATGTTTACA GTCGATTCTT TTCCTCCGAC CGTTGTATTG

PstI
+1  Arg Glu Gln Ala Asn Leu Asn Ser Arg Thr Glu Glu Thr Ile Lys Phe Ala
301 AGAGAACAGG CCAACCTCAA CTCAAGGACA GAAGAGACTA TAAATTTGTC
   TCTCTTGTC GGTGAGGAGT GAGTTCCTGT CTTCTCTGAT ATTTTAAACG

DpnI
BglII
+1  Ala Ala Ala His Tyr Asn Thr Glu Ile Leu Lys Ser Ile Asp Asn Glu Trp Arg
351 TGCAGCACAT TATAATACAG AGATCTTGAA AAGTATTGAT AATGAGTGGA
   ACGTCGTGTA ATATTATGTC TCTAGAACTT TTCATAACTA TTACTCACCT

SphI
+1  Arg Lys Thr Gln Cys Met Pro Arg Glu Val Cys Ile Asp Val Gly Lys Glu
401 GAAAGACTCA ATGCATGCCA CGGGAGGTGT GTATAGATGT GGGGAAGGAG
   CTTTCTGAGT TACGTACGGT GCCCTCCACA CATATCTACA CCCCTTCCTC

NruI
DraI
AccI
+1  Phe Gly Val Ala Thr Asn Thr Phe Phe Lys Pro Pro Cys Val Ser Val Tyr
451 TTTGGAGTCG CGACAAACAC CTTCTTTAAA CCTCCATGTG TGTCCGTCTA
   AAACCTCAGC GCTGTTTGTG GAAGAAATTT GGAGGTACAC ACAGGCAGAT

AccI
PstI
+1  Tyr Arg Cys Gly Gly Cys Cys Asn Ser Glu Gly Leu Gln Cys Met Asn Thr Ser
501 CAGATGTGGG GGTGCTGCA ATAGTGAGGG GCTGCAGTGC ATGAACACCA
   GTCTACACCC CCAACGACGT TATCACTCCC CGACGTCACG TACTTGTTGGT

```



Ddel  
~~~~~

EagI  
~~~~~

NotI  
~~~~~

+1 Pro Ser Tyr Trp Lys Arg Pro Gln Met Ser \*\*\*

1251 TTCATATTGG AAAAGACCAC AAATGAGCTA AGCGGCCGCG  
AAGTATAACC TTTTCTGGTG TTTACTCGAT TCGCCGGCGC

---

# STRAIN SHEET

STRAIN CMV I

STORAGE NUMBER 11-64

## PEDIGREE:

-CMV I was constructed in the pSV7 (nee pSG5 from Stratagene, with an expanded polylinker) backbone by replacing the SV40 promoter from pSV7 with the CMV promoter/enhancer/intron, via 5' Sal I/Xho I (sites destroyed) and 3' Hind III.

-CMV I is 4613 bp.

-CMV I uses ampicillin resistance.


-CMV promoter/enhancer + Intron A: nt #'s 1-1566.

-Polylinker: nt #'s 1566-1597 (5' - Hind III - Eco RI - Bam HI - Not I - Bgl II - 3').

-SV40 polyA addition sequence: nt #'s 1598-1745.

-If for some reason you want to remove the SV40 polyA addition sequence, you can cut with either Sal I or Xba I (these 2 sites border the 3' end of this sequence).

## GROWTH REQUIREMENTS:



Appendix II

kDa

-148

-98


-64

-50

-36

-22


-16




1 2 3 4 5 6 7 8

Power Declaration

Figure 1 Gel 1



Power Declaration  
 Figure 1 - Gel 2



Power Declaration  
Figure 1 - Gel 3